MRK - Merck & Co., Inc.

NYSE - NYSE Delayed Price. Currency in USD
69.98
-0.44 (-0.62%)
At close: 4:00PM EDT

69.98 0.00 (0.00%)
After hours: 4:37PM EDT

Stock chart is not supported by your current browser
Previous Close70.42
Open70.15
Bid69.25 x 1100
Ask70.24 x 1200
Day's Range69.64 - 70.57
52 Week Range52.83 - 70.94
Volume7,944,187
Avg. Volume8,301,459
Market Cap186.114B
Beta1.06
PE Ratio (TTM)144.29
EPS (TTM)0.49
Earnings DateOct 25, 2018
Forward Dividend & Yield1.92 (2.74%)
Ex-Dividend Date2018-09-14
1y Target Est72.88
Trade prices are not sourced from all markets
  • Can Accenture Meet Its Operating Margin Guidance in Q4 2018?
    Market Realist10 hours ago

    Can Accenture Meet Its Operating Margin Guidance in Q4 2018?

    Accenture (ACN) has forecast its operating margin for fiscal 2018 at 14.8%, which would be higher than its fiscal 2017 margin of 12.9%. In the past five quarters, it mostly sustained a double-digit operating margin. In the chart below, you can see its GAAP operating margin trend in the last five quarters.

  • Pharma Stocks in Review: A Valuation Comparison
    Market Realist10 hours ago

    Pharma Stocks in Review: A Valuation Comparison

    In this article, we’ll compare the valuations of Eli Lilly and Company (LLY), Pfizer (PFE), Merck & Co. (MRK), Allergan (AGN), and GlaxoSmithKline (GSK).

  • Accenture, Merck & Amazon AWS Partner for Cloud Platform
    Zacks23 hours ago

    Accenture, Merck & Amazon AWS Partner for Cloud Platform

    Accenture's (ACN) latest partnership is likely to boost its Products segment.

  • MarketWatchyesterday

    Health care ETF surges toward record in a broad sector rally

    The SPDR Health Care Select Sector ETF rose 0.7% toward a record high in afternoon trade Tuesday, with 55 of its 63 equity components gaining ground. Among the ETF's (XLV) members which are also Dow Jones Industrial Average components, Pfizer Inc.'s stock shot up 1.5%, putting it on track to close at the highest level since December 2001. Also, shares of Johnson & Johnson gained 0.6% toward an eight-month high, Merck & Co. Inc. tacked on 0.4% to sit just shy of its 17-year high reached last Thursday, and UnitedHealth Group Inc. slipped 0.1% and was 2.2% below its Sept. 6 record close of $269.65. The XLV's biggest gainer was Abiomed Inc.'s stock , which rallied 2.7%, while its biggest decliner was AbbVie Inc.'s stock , which shed 2.1% after California sued the company alleging the payment of illegal kickbacks. The XLV has rallied 11% over the past three months, while the Dow has tacked on 5.2%.

  • A Review of Pharma Stocks’ EPS Growth Rates
    Market Realistyesterday

    A Review of Pharma Stocks’ EPS Growth Rates

    In this article, we’ll compare the EPS growth rates of pharmaceutical companies Eli Lilly and Company (LLY), Pfizer (PFE), Merck & Co. (MRK), Allergan (AGN), and GlaxoSmithKline (GSK).

  • Exploring Pharmaceutical Stocks’ Revenue Growth Rates
    Market Realistyesterday

    Exploring Pharmaceutical Stocks’ Revenue Growth Rates

    In this article, we’ll compare the revenue growth rates of the pharmaceutical companies under review in this series: Eli Lilly and Company (LLY), Pfizer (PFE), Merck & Co. (MRK), Allergan (AGN), and GlaxoSmithKline (GSK).

  • Can Pfizer (PFE) Bank on Bavencio for Long-Term Growth?
    Zacksyesterday

    Can Pfizer (PFE) Bank on Bavencio for Long-Term Growth?

    Pfizer's (PFE) latest anti-PD-L1 immunotherapy, Bavencio, is being touted as a significant long-term top-line driver for the company.

  • A Look at the Dividends Paid by Pharma Stocks in 2018
    Market Realistyesterday

    A Look at the Dividends Paid by Pharma Stocks in 2018

    In this article, we’ll discuss the details of the dividends paid by pharmaceutical stocks Eli Lilly and Company (LLY), Pfizer (PFE), Merck & Co. (MRK), Allergan (AGN), and GlaxoSmithKline (GSK).

  • Delstrigo, Pifeltro, and Merck’s Antiviral Therapy Portfolio
    Market Realistyesterday

    Delstrigo, Pifeltro, and Merck’s Antiviral Therapy Portfolio

    In the second quarter, Merck’s (MRK) Zepatier and Isentress reported revenues of $113.0 million and $305.0 million, respectively, which represented an ~78.0% decline and 8.0% growth on a YoY (year-over-year) basis. In the first half, Zepatier and Isentress reported net revenues of $243.0 million and $586.0 million, respectively.

  • A Look at the Market Caps of the Pharma Stocks under Review
    Market Realist2 days ago

    A Look at the Market Caps of the Pharma Stocks under Review

    As we discussed earlier, a few of the pharmaceutical stocks that have surpassed the returns of the S&P 500 Index YTD (year-to-date) include Eli Lilly and Company (LLY), Pfizer (PFE), Merck & Co. (MRK), Allergan (AGN), and GlaxoSmithKline (GSK). Let’s take a look at the details of their market caps.

  • How Pharmaceutical ETFs Have Performed in 2018
    Market Realist2 days ago

    How Pharmaceutical ETFs Have Performed in 2018

    Pharmaceutical ETFs are securities that are publicly traded on stock markets designed for investors who don’t have the capacity to hold many stocks but are interested in diversification within the pharmaceutical sector.

  • Lenvima Could Significantly Boost Merck’s Revenue Growth
    Market Realist2 days ago

    Lenvima Could Significantly Boost Merck’s Revenue Growth

    In August, the FDA approved Merck’s (MRK) and Eisai’s Lenvima in the first-line setting for the treatment of individuals with unresectable hepatocellular carcinoma (or HCC). The FDA’s approval of Lenvima in the first-line setting for the treatment of HCC was based on data from the REFLECT trial.

  • Keytruda Could Boost Merck’s Revenue Growth in 2018 and Beyond
    Market Realist2 days ago

    Keytruda Could Boost Merck’s Revenue Growth in 2018 and Beyond

    On September 12, Merck (MRK) announced that the FDA accepted for review the company’s new supplemental Biologics License Application (or sBLA) for the label expansion of Keytruda. Merck seeks label expansion of Keytruda for approval as a monotherapy in the first-line setting. This treatment is intended for individuals with metastatic nonsquamous or squamous NSCLC (non-small cell lung cancer) with tumors expressing PD-L1 without EGFR or ALK genomic tumor abnormalities.

  • How Is Merck’s Keytruda Positioned in September?
    Market Realist2 days ago

    How Is Merck’s Keytruda Positioned in September?

    Merck’s (MRK) Keytruda has witnessed ~89% YoY (year-over-year) growth and generated second-quarter revenues of $1.7 billion. In the US market, Keytruda’s second-quarter revenues grew 73.0% to reach $959.0.0 million. In the international markets, Keytruda’s revenues increased ~118.0% YoY to reach $707.0.0 million.

  • Wall Street Analysts Are Mostly Positive on Merck in September
    Market Realist5 days ago

    Wall Street Analysts Are Mostly Positive on Merck in September

    Merck (MRK) recently announced that its pivotal Phase 3 trial that evaluated Zerbaxa met its primary endpoint. Zerbaxa is an investigational antibiotic for the treatment of adult individuals with ventilated hospital-acquired bacteria pneumonia or ventilator-associated bacterial pneumonia (or VABP). Zerbaxa demonstrated non-inferiority compared to meropenem.

  • Pharma Stock Roundup: AZN's Leukemia Drug Wins FDA Nod, MRK's Keytruda in Focus
    Zacks5 days ago

    Pharma Stock Roundup: AZN's Leukemia Drug Wins FDA Nod, MRK's Keytruda in Focus

    Label expansion of Merck's (MRK) Keytruda and FDA approval of AstraZeneca's (AZN) leukemia drug grab headlines this week

  • Are Options Traders Betting on a Big Move in Merck (MRK) Stock?
    Zacks5 days ago

    Are Options Traders Betting on a Big Move in Merck (MRK) Stock?

    Investors need to pay close attention to Merck (MRK) stock based on the movements in the options market lately.

  • Dow 30 Stock Roundup: Apple Unveils 3 New iPhones, Boeing Clinches $2.9B Deal
    Zacks5 days ago

    Dow 30 Stock Roundup: Apple Unveils 3 New iPhones, Boeing Clinches $2.9B Deal

    The index chalked up gains this week amid renewed hopes of trade talks between the United States and China.

  • Allergan Unveils Spotlyte, Its First Digital Ventures Launch
    Market Realist6 days ago

    Allergan Unveils Spotlyte, Its First Digital Ventures Launch

    On September 12, Allergan (AGN) announced the launch of Spotlyte, the first launch from Project Moonwalker, the Allergan-owned digital ventures unit. Spotlyte is an innovative digital hub designed to educate consumers about medical aesthetic treatments. The below chart lists key updates on Spotlyte. Spotlyte is the first venture from Project Moonwalker and is designed to educate consumers about medical aesthetics.

  • Merck Gets Priority Review for Yet Another Keytruda sBLA
    Zacks6 days ago

    Merck Gets Priority Review for Yet Another Keytruda sBLA

    Merck's (MRK) sBLA to include overall survival data from a key lung cancer study on Keytruda's label gets FDA's priority review. If approved, it will expand the eligible patient population.

  • What Analysts Project for Thermo Fisher
    Market Realist6 days ago

    What Analysts Project for Thermo Fisher

    Wall Street analysts estimate Thermo Fisher Scientific (TMO) to report 14.1% growth in revenues to ~$23.9 billion in full-year 2018 as compared to $20.9 billion during 2017. EPS is estimated to be $10.99 during 2018 as compared to EPS of $9.49 during 2017. Analysts estimate the net adjusted income to increase to $4.5 billion during 2018 as compared to the net adjusted income of $3.8 billion during 2017.

  • Is Merck & Co Inc’s (NYSE:MRK) Balance Sheet Strong Enough To Weather A Storm?
    Simply Wall St.6 days ago

    Is Merck & Co Inc’s (NYSE:MRK) Balance Sheet Strong Enough To Weather A Storm?

    There are a number of reasons that attract investors towards large-cap companies such as Merck & Co Inc (NYSE:MRK), with a market cap of US$183.72b. Doing business globally, large capsRead More...

  • Roche CEO Refuses to Cede Cancer's Hottest New Field to Merck
    Bloomberg6 days ago

    Roche CEO Refuses to Cede Cancer's Hottest New Field to Merck

    Roche Holding AG is refusing to cede the hottest new area of cancer care to Merck & Co. despite trailing its U.S. rival. Merck’s immune therapy Keytruda has dominated the market, with analysts predicting it will deliver more than $10 billion in annual sales by 2020. Roche still believes it can be a leader in the field of drugs designed to unleash the body’s immune system against tumors, with positive results for its own contender Tecentriq coming at two conferences this fall, Chief Executive Officer Severin Schwan said in an interview.

  • Merck's Antibacterial Drug Succeeds in Label Expansion Study
    Zacks7 days ago

    Merck's Antibacterial Drug Succeeds in Label Expansion Study

    Merck's (MRK) label expansion study evaluating its antibacterial drug, Zerbaxa for two types of pneumonia infections meets primary endpoints.

  • Immunotherapy for NSCLC: 4 Large-Cap Pharma Stocks in Focus
    Zacks7 days ago

    Immunotherapy for NSCLC: 4 Large-Cap Pharma Stocks in Focus

    Here we take a look at companies with approved immunotherapy therapies or pipeline candidates for the treatment of widely prevalent NSCLC.